ELDN - Eledon Pharmaceuticals, Inc.
IEX Last Trade
4.355
0.015 0.344%
Share volume: 25,747
Last Updated: Fri 27 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$4.34
0.02
0.35%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.30%
1 Month
2.58%
3 Months
75.50%
6 Months
68.08%
1 Year
145.51%
2 Year
88.36%
Key data
Stock price
$4.36
DAY RANGE
$4.20 - $4.39
52 WEEK RANGE
$1.64 - $5.54
52 WEEK CHANGE
$142.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: David-Alexandre C. Gros
Region: US
Website: https://eledon.com/
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://eledon.com/
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Eledon Pharmaceuticals, Inc. focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS.
Recent news